Infliximab Response in Inflammatory Bowel Disease

Overview

About this study

The specific objectives of this study are to define infliximab thresholds during induction therapy and during maintenance therapy (visit 6) that are associated with good prognosis/response, study the correlation of inflammation markers such as serum CRP and fecal calprotectin with infliximab and antibodies-to-infliximab, and evaluate  how soon after initiation of therapy there is development of antibodies-to-infliximab

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Mayo Clinic patient
  • Naïve to infliximab
  • Older than 18 years old
  • All infliximab infusions administered on Mayo Clinic campus

Exclusion Criteria: 

  • Use of infliximab in the past
  • Pregnancy.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Melissa Snyder, Ph.D.

Closed for enrollment

Contact information:

Maria Alice Willrich Ph.D.

(507)266-4909

Willrich.MariaAlice@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20308930

Mayo Clinic Footer